Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Vascular disorders – page 2

  • 846 clinical trials
  • 351 recruiting
  • 382 conditions
  • 28 countries

Conditions in this area

382 conditions with trials, the busiest first

Ischaemic stroke52Migraine48Pulmonary arterial hypertension41Systemic scleroderma40Coronary artery disease37Arteriosclerosis32Acute myocardial infarction30Hypertension29Pulmonary hypertension24Acute coronary syndrome21Giant cell arteritis18Paroxysmal nocturnal haemoglobinuria17Peripheral arterial occlusive disease17Septic shock17Cardiovascular disorder16Subarachnoid haemorrhage16Acute respiratory distress syndrome15Atrial fibrillation15Anti-neutrophil cytoplasmic antibody positive vasculitis14Cerebrovascular accident14Pulmonary embolism14Embolism13Myocardial infarction13Diabetic foot12+358

Clinical trials in Vascular disorders

846 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

846 clinical trials

Acute coronary syndrome

Recruiting

Study on Metformin's Effect in Reducing Unplanned Heart Procedures in Non-Diabetic Patients with Acute Coronary Syndrome

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Metformin Hydrochloride
  • Sponsor:Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy

Myocardial infarction

Recruiting

Study on the Effects of Ferric Carboxymaltose on Heart Health and Quality of Life in Patients with Recent Heart Attack and Iron Deficiency

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Agencja Badań Medycznych

Acute myocardial infarction

Recruiting

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Giant cell arteritis

Recruiting

Study on the Effectiveness of Etanercept and Methotrexate for Patients with Giant Cell Arteritis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Etanercept
  • Sponsor:Agencja Badań Medycznych

Coronary artery disease

Recruiting

Study on the Use of SYN2, Adenosine, and Regadenoson for Diagnosing Coronary Artery Disease in Patients with Suspected Heart Conditions

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Adenosine

Hepatic fibrosis+2

Recruiting

Study on Efruxifermin for Patients with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efruxifermin
  • Sponsor:Akero Therapeutics Inc.

Coronary artery disease

Recruiting

Study on Coronary Artery Disease: Evaluating Myocardial Blood Flow Using SYN2, Regadenoson, and Adenosine in Patients with Heart Conditions

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Adenosine
  • Sponsor:Synektik S.A.

Arteriosclerosis

Recruiting

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Cushing's syndrome

Recruiting

Efficacy and safety of osilodrostat with drug combination in patients with hypertension caused by Cushing's syndrome

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Recordati AG

Hereditary haemorrhagic telangiectasia

Recruiting

A Phase 3 Study of Engasertib to Evaluate Safety and Effectiveness in Adults with Moderate to Severe Hereditary Hemorrhagic Telangiectasia

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Vaderis Therapeutics AG

Coronary artery disease

Recruiting

Safety and Pharmacodynamic Study of Subcutaneous RBD1119 in Adults with Coronary Artery Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Ribocure Pharmaceuticals AB

Coronary artery disease+2

Recruiting

Study of YMI024 to Reduce Inflammation in Adults with Stable Coronary Artery Disease and Elevated hsCRP

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Acetylsalicylic Acid59 clinical trialsSodium Chloride55 clinical trialsClopidogrel33 clinical trialsApixaban28 clinical trialsTicagrelor28 clinical trialsRivaroxaban21 clinical trialsAtorvastatin17 clinical trialsPrasugrel17 clinical trialsRituximab16 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.